Charles River Laboratories International, Inc. (NYSE:CRL) has been given a $117.00 price target by equities researchers at Robert W. Baird in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the medical research company’s stock. Robert W. Baird’s price target points to a potential upside of 15.93% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Barclays PLC reissued a “hold” rating and set a $102.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Bank of America Corporation cut their target price on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Finally, ValuEngine lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $106.05.

Shares of Charles River Laboratories International (NYSE:CRL) opened at $100.92 on Monday. Charles River Laboratories International has a 12-month low of $69.51 and a 12-month high of $119.05. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. The firm has a market cap of $4,827.56, a price-to-earnings ratio of 20.03, a PEG ratio of 1.63 and a beta of 0.94.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. Charles River Laboratories International’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 earnings per share. research analysts anticipate that Charles River Laboratories International will post 5.13 EPS for the current year.

WARNING: “Charles River Laboratories International, Inc. (CRL) PT Set at $117.00 by Robert W. Baird” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/15/charles-river-laboratories-international-inc-crl-pt-set-at-117-00-by-robert-w-baird.html.

In other news, insider Davide Molho sold 5,982 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total value of $643,364.10. Following the completion of the sale, the insider now owns 22,714 shares in the company, valued at $2,442,890.70. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Over the last ninety days, insiders acquired 10,500 shares of company stock worth $2,885 and sold 1,016,147 shares worth $1,991,154. 2.20% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in CRL. YorkBridge Wealth Partners LLC raised its holdings in shares of Charles River Laboratories International by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Charles River Laboratories International by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 548 shares during the last quarter. Advisor Group Inc. raised its holdings in shares of Charles River Laboratories International by 159.4% in the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 945 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 202 shares during the last quarter. Finally, Riverhead Capital Management LLC raised its holdings in shares of Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the last quarter. Institutional investors own 97.46% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.